List of Excipients in Branded Drug FLUOXETINE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alvogen Inc	FLUOXETINE HYDROCHLORIDE	fluoxetine hydrochloride	47781-600	CELLULOSE, MICROCRYSTALLINE
Alvogen Inc	FLUOXETINE HYDROCHLORIDE	fluoxetine hydrochloride	47781-600	GLYCERIN
Alvogen Inc	FLUOXETINE HYDROCHLORIDE	fluoxetine hydrochloride	47781-600	HYPROMELLOSE
Alvogen Inc	FLUOXETINE HYDROCHLORIDE	fluoxetine hydrochloride	47781-600	MAGNESIUM STEARATE
Alvogen Inc	FLUOXETINE HYDROCHLORIDE	fluoxetine hydrochloride	47781-600	MANNITOL
Alvogen Inc	FLUOXETINE HYDROCHLORIDE	fluoxetine hydrochloride	47781-600	POLYSORBATE 80

Generic Drugs Containing FLUOXETINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
NCS HealthCare of KY Inc dba Vangard Labs	fluoxetine hydrochloride	0615-1387	D&C YELLOW NO. 10
NCS HealthCare of KY Inc dba Vangard Labs	fluoxetine hydrochloride	0615-1387	FD&C BLUE NO. 1
NCS HealthCare of KY Inc dba Vangard Labs	fluoxetine hydrochloride	0615-1387	FERRIC OXIDE RED
NCS HealthCare of KY Inc dba Vangard Labs	fluoxetine hydrochloride	0615-1387	FERRIC OXIDE YELLOW
NCS HealthCare of KY Inc dba Vangard Labs	fluoxetine hydrochloride	0615-1387	GELATIN
NCS HealthCare of KY Inc dba Vangard Labs	fluoxetine hydrochloride	0615-1387	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in FLUOXETINE HYDROCHLORIDE?

# Of NDCs	Excipient
2	ALCOHOL
2	BENZOIC ACID
22	CELLULOSE, MICROCRYSTALLINE
6	CROSCARMELLOSE SODIUM
14	CROSPOVIDONE
12	D&C YELLOW NO. 10

Fluoxetine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 21, 2026

Fluoxetine hydrochloride is a mature, low-cost SSRI with limited active patent protection and substantial generic competition. The strongest commercial opportunities are formulation-led: palatable oral liquids, pediatric-friendly dosage forms, orally disintegrating tablets, sprinkle capsules, modified-release products, and excipient systems that improve manufacturing, stability, or adherence. Conventional immediate-release capsules remain difficult to differentiate on price alone.

What is the regulatory and commercial status of fluoxetine hydrochloride?

Fluoxetine hydrochloride is the hydrochloride salt of fluoxetine, a selective serotonin reuptake inhibitor approved in the United States for major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder, depending on dosage form and labeling. Eli Lilly originally marketed the product as Prozac.

The FDA approved Prozac capsules in 1987. Other approved dosage forms include oral solution, tablets, and a once-weekly delayed-release capsule. Generic fluoxetine products are widely available through ANDA approvals.

Attribute	Fluoxetine hydrochloride
Originator	Eli Lilly and Company
Originator brand	Prozac
Therapeutic class	Selective serotonin reuptake inhibitor
Common strengths	10 mg, 20 mg, 40 mg
Weekly strength	90 mg delayed-release capsule
Common dosage forms	Capsule, tablet, oral solution, delayed-release capsule
FDA pathway for generics	ANDA
Core composition patent	Expired
Current market structure	Highly genericized
Primary commercial opportunity	Differentiated delivery, taste, adherence, and manufacturing performance

The base product is commercially mature. A new conventional capsule is likely to compete primarily through API cost, conversion yield, supply reliability, packaging, and channel access. Excipient differentiation becomes more valuable when linked to a distinct dosage form or a clinically relevant administration advantage.

What excipients are used in fluoxetine hydrochloride products?

The excipient profile varies by manufacturer, dosage form, strength, and jurisdiction. FDA-approved labels and DailyMed listings show that fluoxetine products can use standard capsule, tablet, and oral-liquid excipients rather than a single market-wide formulation.

Immediate-release capsules

Typical excipient categories include:

• Lactose or another diluent
• Microcrystalline cellulose
• Pregelatinized starch or starch
• Colloidal silicon dioxide
• Magnesium stearate
• Gelatin capsule shells
• Titanium dioxide and permitted colorants
• Printing inks

The most important technical variables are powder flow, blend uniformity, capsule-fill weight control, dissolution, moisture control, and compatibility with the relatively low drug load in some strengths.

Fluoxetine hydrochloride is pharmacologically potent at conventional dose levels. Low-dose capsules therefore require reliable content uniformity and segregation control. A formulation that uses a carrier-based premix, ordered mixing, or engineered granules can reduce content-uniformity risk even when the excipients themselves are conventional.

Tablets

Immediate-release tablets may use:

• Lactose or mannitol as a filler
• Microcrystalline cellulose as a compression aid
• Croscarmellose sodium, crospovidone, or sodium starch glycolate as a disintegrant
• Povidone as a binder
• Colloidal silicon dioxide as a glidant
• Magnesium stearate or sodium stearyl fumarate as a lubricant
• Film-coating polymers such as hypromellose
• Polyethylene glycol, talc, titanium dioxide, and colorants

A tablet strategy can target smaller dimensions, rapid disintegration, low friability, and improved swallowability. The commercial value is higher when the product is designed for patients who have difficulty swallowing capsules or tablets.

Oral solution

Fluoxetine oral solution is generally based on an aqueous vehicle with a sweetener, humectant, preservative, flavor system, and pH-control elements. Public product labeling has identified excipient systems including sucrose, glycerin, benzoic acid, purified water, and flavoring, although the exact formulation depends on the product.

The liquid format creates several development requirements:

• Taste masking against the bitter or unpleasant drug profile
• Preservative efficacy
• Microbiological control
• Chemical stability over the proposed shelf life
• Accurate dosing through a syringe or calibrated measuring device
• Compatibility with dosing accessories
• Control of sugar, sodium, alcohol, and allergen declarations

A liquid product can command a stronger commercial position than a standard capsule if it improves pediatric or geriatric administration. The principal risk is that a simple sweetener-and-flavor approach may be commercially inadequate if the active ingredient remains perceptible after dilution or prolonged mouth contact.

What excipient strategies can differentiate fluoxetine products?

The most credible strategies fall into five categories: palatability, disintegration, modified release, manufacturing robustness, and patient-specific excipient selection.

Taste-masked oral liquids

Fluoxetine liquid products can use a multi-layer taste strategy:

1. Reduce drug release in the mouth through pH control or ion-pairing.
2. Add a sweetener system with immediate and lingering sweetness.
3. Use a flavor profile capable of masking bitterness after dilution.
4. Control viscosity to reduce tongue exposure without impairing syringe dosing.
5. Confirm acceptability in the target pediatric or adult population.

Potential excipient tools include ion-exchange resins, cyclodextrins, polymeric complexing agents, emulsions, and coated drug particles. Each approach creates a different regulatory burden. A resin complex or encapsulated particle system may support a stronger product story than a conventional flavored solution, but it also requires comparative dissolution, dose-uniformity, stability, and bioavailability work.

Orally disintegrating tablets

An orally disintegrating tablet, or ODT, could target patients who cannot swallow conventional solid dosage forms. A viable ODT platform would normally require:

• A rapidly wetting filler such as mannitol
• A superdisintegrant
• A taste-masking system
• Low compression force sufficient to preserve fast disintegration
• Adequate mechanical strength during packaging and transport
• Moisture-protective packaging

Fluoxetine has a bitter taste profile, so an ODT without effective taste masking would have limited value. The commercial opportunity is therefore tied to taste-masked microparticles, coated granules, or a multiparticulate matrix rather than disintegration speed alone.

An ODT may be pursued through an ANDA if the product can demonstrate equivalence within the applicable FDA framework. A formulation that changes absorption, local exposure, or administration conditions may require a 505(b)(2) strategy instead.

Sprinkle or openable capsule

A sprinkle formulation could provide an administration option for patients who cannot swallow intact capsules. Key design questions include:

• Whether pellets can be mixed with soft food
• Whether the drug remains stable after opening
• Whether the pellets can be swallowed without chewing
• Whether the food matrix changes dissolution
• Whether the capsule is suitable for the intended patient population

Multiparticulate pellets can support taste masking and modified release, but the product label must control administration instructions. This type of product may be more commercially defensible than a conventional capsule if the formulation provides a documented administration advantage.

Modified-release systems

Fluoxetine already has a once-weekly 90 mg delayed-release product. The commercial lesson is that modified release can create a differentiated adherence proposition, but the product must overcome several challenges:

• Long exposure duration
• Dose dumping risk
• Food effects
• Delayed-release reproducibility
• Pharmacokinetic variability
• Packaging and stability of coated pellets or multiparticulates

An enteric-coated pellet system may use a seal coat, an enteric polymer, a plasticizer, anti-tacking agents, and a capsule shell. Candidate enteric polymers include methacrylic acid copolymers and cellulose acetate phthalate-type systems, subject to product-specific development and regulatory acceptability.

A new weekly or extended-interval product would face a higher development burden than an immediate-release generic. The opportunity is strongest where a sponsor can demonstrate adherence or administration benefits and support the product with a clear clinical and regulatory pathway.

Manufacturing-focused excipient systems

For standard capsules, excipient innovation is most likely to produce cost and quality advantages rather than pricing power. Relevant targets include:

• Direct-compression blends with better flow
• Reduced lubricant sensitivity
• Lower tablet ejection force
• Improved low-dose content uniformity
• Reduced dusting and occupational exposure
• Better moisture resistance
• Faster dissolution after scale-up
• Fewer unit operations

Co-processed excipients may improve flow and compression, but the sponsor must evaluate supplier qualification, change-control exposure, supply continuity, and regulatory documentation. The best manufacturing platform is not necessarily the one with the fewest excipients. It is the one that delivers reproducible quality at commercial scale with a stable supply base.

What FDA regulatory pathway applies to new fluoxetine formulations?

A conventional immediate-release fluoxetine product can generally be developed through an ANDA when the product meets the applicable reference-product, dosage-form, strength, route, labeling, and bioequivalence requirements. Differences in inactive ingredients are permitted when they are acceptable under FDA requirements and do not affect safety, efficacy, or performance.

The FDA Inactive Ingredient Database is a central screening tool for excipient selection. Sponsors should compare proposed excipient levels with previously approved exposure levels for the same route and dosage form. A new excipient, substantially higher exposure, or materially different delivery system may increase the need for additional toxicology, clinical, or regulatory justification (FDA, n.d.-a).

A 505(b)(2) application may be more appropriate for:

• A new dosage form
• A new route of administration
• A clinically meaningful modified-release system
• A new strength not directly supported by an ANDA pathway
• A product with a new administration method
• A formulation that relies partly on published literature or FDA findings for the listed drug

The regulatory pathway should be selected early because it determines the scale of comparative pharmacokinetic, clinical, stability, and human-factors work.

What patents protect fluoxetine hydrochloride products?

The original composition-of-matter and broad product protection for fluoxetine has expired. The historical core patent was U.S. Patent No. 4,314,081, assigned to Eli Lilly, covering fluoxetine-related compounds and issued before the modern 20-year-from-priority patent-term system. That protection no longer prevents generic manufacture.

IP category	Current commercial relevance
Original fluoxetine composition patent	Expired
Original Prozac product protection	Expired
Conventional immediate-release capsule patents	Generally no meaningful originator barrier
Oral-solution formulation patents	Must be reviewed product by product
Weekly delayed-release formulation patents	Historical protection must be checked against current expiration and listing status
New excipient or delivery patents	Available for new, non-obvious formulations
Manufacturing-process patents	Potentially relevant where process conditions are difficult to replicate

Patent risk has shifted from the active ingredient to formulation execution. A sponsor could seek protection for a taste-masked liquid, a specific coated multiparticulate, a stable ODT, a defined excipient ratio, a manufacturing process, or a patient-use method. Such patents must satisfy novelty, non-obviousness, written description, enablement, and enforceability requirements.

A broad claim to "fluoxetine with an excipient" is unlikely to be commercially strong. A narrower claim tied to measurable performance, such as a defined dissolution profile, reduced mouth exposure, stability threshold, particle-coating structure, or administration condition, is more defensible if adequately supported.

What is the Orange Book and Paragraph IV status of fluoxetine?

Fluoxetine generic competition is not principally constrained by a live Orange Book patent estate for the original immediate-release product. Historical ANDA filings may have used Paragraph IV certifications against listed patents during the generic-entry period, but the principal composition protection is now expired.

For a current product launch, the relevant review should include:

• Current Orange Book entries for Prozac and related dosage forms
• Active patent listings associated with the specific reference product
• Any unexpired formulation or method-of-use patents
• Pediatric exclusivity or other exclusivity attached to a listed product
• The reference product's dosage form and strength
• FDA approval status of the proposed generic
• Litigation records in the U.S. District Court and Federal Circuit

Paragraph IV litigation is more likely to arise for a new delayed-release, weekly, or otherwise differentiated formulation than for a basic 10 mg, 20 mg, or 40 mg immediate-release capsule. A sponsor pursuing a new delivery system should expect claim construction, obviousness, written-description, and infringement issues around coating composition, release timing, pharmacokinetic parameters, and administration methods.

Which companies are challenging the fluoxetine market?

The immediate-release market is populated by multiple generic manufacturers and contract manufacturers. Product availability changes by strength and presentation. Major generic participants historically have included Teva, Mylan or Viatris, Sandoz, Apotex, Dr. Reddy's, Aurobindo, and other FDA-approved suppliers.

The relevant competitive dimensions are:

Competitive factor	Importance
API cost and supply	High for standard capsules
Manufacturing yield	High
Retail price	High
Shortage resilience	Increasingly important
Liquid palatability	High in pediatric and geriatric segments
Dosage-form convenience	High for differentiated products
Patent position	Low for standard immediate-release products
Pharmacy substitution	High in generic channels
Formulary access	High
Packaging and adherence support	Moderate to high

A sponsor should not assume that a formulation patent alone will generate market share. Pharmacy substitution, wholesaler access, reimbursement, and reliable supply often determine commercial performance in a mature generic category.

How strong is the fluoxetine patent estate for new excipient products?

The legacy fluoxetine estate is weak as a barrier to entry because the active-ingredient protection has expired. A new formulation estate can be stronger if it combines several claim types:

• Composition claims covering a defined excipient system
• Particle or coating claims
• Dissolution claims
• Stability claims
• Manufacturing-process claims
• Dosage-regimen claims
• Method-of-use claims for a defined patient group

Patent strength depends on more than claim count. A practical assessment should consider:

1. Whether the claims cover a commercially necessary feature.
2. Whether competitors can design around the excipient system.
3. Whether the claimed parameters are easy to measure.
4. Whether the product's commercial performance depends on the claimed feature.
5. Whether the claims are supported by comparative data.
6. Whether the formulation can be reverse-engineered from the marketed product.
7. Whether an ANDA or 505(b)(2) applicant can avoid infringement through a different delivery platform.

For fluoxetine, a layered formulation portfolio is more valuable than a single broad excipient patent. Trade secrets may protect manufacturing order, granulation endpoint, coating parameters, and process controls that are difficult to infer from the finished product.

What geographic opportunities exist for fluoxetine formulations?

The United States is a mature generic market. Commercial opportunities outside the United States depend on local prescription patterns, regulatory requirements, pediatric formulations, and the availability of competing SSRIs.

Potential geographic priorities include:

• Markets with weak access to palatable pediatric liquids
• Regions where oral liquids are preferred for dose flexibility
• Countries with limited availability of weekly or adherence-oriented products
• Markets where local manufacturing incentives favor formulation transfer
• Jurisdictions accepting well-established-use or abridged applications
• Countries where excipient restrictions differ from U.S. requirements

The excipient strategy must be localized. Sweeteners, preservatives, colorants, titanium dioxide, alcohol content, animal-derived gelatin, and allergen declarations can affect approval and marketability across jurisdictions. A global product should use excipients with broad compendial acceptance and established regulatory history.

What commercial opportunities exist for fluoxetine hydrochloride?

The strongest opportunities are formulation-led rather than API-led.

Higher-potential opportunities

Product concept	Commercial rationale	Main development risk
Palatable oral solution	Pediatric and swallowing-constrained populations	Taste, preservative efficacy, stability
Low-sugar or sugar-free liquid	Diabetes, dental, and preference considerations	Taste and viscosity
ODT	Convenience and swallowing support	Bitter taste and mechanical strength
Sprinkle capsule	Administration flexibility	Food interaction and label complexity
Improved weekly product	Adherence and reduced dosing frequency	PK, release control, clinical differentiation
Unit-dose liquid	Institutional and adherence settings	Packaging cost and stability
Manufacturing-optimized capsule	Lower cost and higher yield	Limited pricing differentiation
Pediatric dose-flexible product	Supports titration and dose adjustment	Clinical usability and regulatory positioning

Lower-potential opportunities

A new standard capsule with the same strength, release profile, and patient instructions is unlikely to generate significant premium pricing unless it offers a measurable manufacturing or supply advantage. A formulation based only on a new flavor, color, or conventional filler may have limited patent durability and weak commercial differentiation.

What litigation and settlement risks affect fluoxetine?

Historical litigation centered on generic entry after expiration or challenge of Eli Lilly's fluoxetine patents. Those disputes were commercially significant during the original Prozac exclusivity period but do not create the same barrier for current immediate-release entrants.

Current litigation risk would more likely involve:

• A newly patented delayed-release product
• A formulation patent covering taste masking
• A coating or multiparticulate system
• A patent on a specific method of use
• Trade-secret misappropriation involving manufacturing
• Contract disputes over API or excipient supply
• ANDA litigation involving a newly listed reference product

Settlement agreements should be reviewed for launch dates, licenses, authorized-generic rights, supply provisions, geographic limitations, and restrictions on formulation development. For standard fluoxetine capsules, a settlement is less likely to be the central commercial issue than manufacturing economics and distribution access.

What is the best excipient strategy for a new fluoxetine product?

The most practical strategy is to select the target patient and commercial channel before selecting the excipients.

For a mass-market generic capsule, prioritize low-cost, robust excipients, supplier redundancy, blend uniformity, and dissolution consistency. For a differentiated product, prioritize one clear administration benefit:

• Pediatric use: taste-masked liquid or sprinkle system
• Dysphagia: ODT or liquid
• Adherence: weekly modified release
• Institutional use: unit-dose liquid or easy-to-administer formulation
• Cost reduction: direct-compression or simplified granulation platform

The formulation should generate comparative data against the relevant reference product. Useful evidence includes dissolution across pH conditions, taste panels, sedimentation or redispersibility, stability, food-effect assessment, dose uniformity, and human-factors testing.

Key Takeaways

• Fluoxetine hydrochloride is a mature, heavily genericized SSRI with expired core composition protection.
• Standard immediate-release capsules offer limited formulation-based pricing power.
• The strongest opportunities are oral liquids, ODTs, sprinkle capsules, and adherence-oriented modified-release products.
• Taste masking is the central technical challenge for pediatric and orally disintegrating formulations.
• The FDA Inactive Ingredient Database should guide excipient selection and exposure assessment.
• ANDA is generally suitable for conventional equivalent products; 505(b)(2) may be required for differentiated dosage forms or delivery systems.
• New patent value will come from formulation, coating, manufacturing, or administration claims rather than the fluoxetine molecule.
• Commercial success depends on pharmacy access, cost, supply reliability, and patient usability as much as on patent scope.
• Geographic strategy must account for excipient restrictions, preservative requirements, pediatric demand, and local regulatory pathways.

FAQs

Can fluoxetine hydrochloride be formulated without lactose?

Yes. Mannitol, microcrystalline cellulose, starch-based fillers, calcium phosphate, and other suitable diluents may replace lactose, subject to manufacturability, dissolution, stability, and regulatory acceptance.

Is a sugar-free fluoxetine oral solution commercially attractive?

It can be attractive where sugar content, dental exposure, diabetes, or patient preference affects product selection. The formulation must preserve palatability, preservative performance, dosing accuracy, and shelf stability.

Can an excipient combination create new fluoxetine patent protection?

Yes, but the claim must cover a novel and non-obvious formulation or performance feature. Conventional combinations of fillers, binders, lubricants, and disintegrants generally provide weak protection without unexpected results or a technically meaningful structure.

Does fluoxetine require an enteric coating?

Immediate-release fluoxetine products do not generally require an enteric coating. An enteric or delayed-release system is relevant to a modified-release product, including a weekly dosage form, and requires product-specific dissolution and pharmacokinetic justification.

What is the main supply-chain risk for fluoxetine products?

The primary risks are API supply concentration, manufacturing-site interruptions, quality failures, and excipient or packaging shortages. A dual-source strategy for API, critical excipients, capsule shells, and dosing devices can reduce launch and continuity risk.

References

1. U.S. Food and Drug Administration. (n.d.-a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. U.S. Food and Drug Administration. (n.d.-b). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.-c). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. DailyMed. (n.d.). Fluoxetine hydrochloride product labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/

5. Eli Lilly and Company. (1982). U.S. Patent No. 4,314,081: N-substituted-3-phenyl-3-(alpha,alpha,alpha-trifluoro-p-tolyl) propylamines. U.S. Patent and Trademark Office.

6. U.S. Food and Drug Administration. (2019). ANDA submissions: Refuse-to-receive standards. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-submissions-refuse-receive-standards

7. U.S. Food and Drug Administration. (2024). Guidance for industry: Size, shape, and other physical attributes of generic tablets and capsules. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/size-shape-and-other-physical-attributes-generic-tablets-and-capsules